

Attorney Docket No.: 5835.200-US

PATENT

#7/B
NB
06/01/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgård-Frantzen et al Serial No.: 09/710,339

Confirmation No: 9183

Group Art Unit: To Be Assigned

Filed: November 9, 2000

Examiner: ~~To Be Assigned~~
MONSHIPOURI

RECEIVED

MAY 31 2001

POST CENTER 1600/2900

For: Fungamyl-like Alpha-Amylase Variants

AMENDMENT AND RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE RULES

Box Sequence
Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to Comply with Sequence Rules dated April 25, 2001, please amend the above-captioned application as follows :

IN THE SPECIFICATION:

Please delete the previously submitted Sequence Listing and insert the attached Sequence Listing (pages 1 -9) at the end of the specification.

REMARKS

Applicants enclose herewith the Sequence Listing for the above-captioned application and a 3.5" floppy disk containing the Sequence Listing.


The specification has been amended to provide SEQ ID NOS for the sequences disclosed therein. This submission contains no new matter.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: May 24, 2001



Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123